A 'symptom-triggered' approach to alcohol withdrawal management by Murdoch, J & Marsden, J
  
A	‘symptom-triggered’	approach	to	alcohol	withdrawal	 management	
Jay	Murdoch	and	Janet		Marsden	
Jay	Murdoch	is	Lead	Nurse	for	Alcohol	Liaison,	Pennine	Acute	Hospitals	NHS	Trust,	Manchester;	Janet	
Marsden	is	Professor	of	Ophthalmology	and	Emergency	Care,	Manchester	Metropolitan	University	
Accepted	for	publication:	February	2014	
	
	
In	acute	hospital	settings,	alcohol	withdrawal	often	causes	significant		management	problems	and	
complicates	a	wide	variety	of	concurrent	conditions,	placing	a	huge	burden	on	the	NHS.	A	significant	
number	of	critical	incidents	around	patients	who	were	undergoing	detoxification	in	a	general	hospital	
setting	led	to	the	need	for	a	project	to	implement	and	evaluate	an	evidence-based	approach	to	the	
management	of	alcohol	detoxification—a		project		that	included	a	pre-intervention		case	note		audit,	
the	implementation	of	an	evidence-based	symptom-triggered	detoxification	protocol,	and	a	post-
intervention	case	note	audit.	This	change	in	practice	resulted	in	an	average	reduction	of	almost	60%	
in	length	of	hospital	stay	and	a	66%	reduction	in	the	amount	of	chlordiazepoxide	used	in	
detoxification,	as	well	as	highlighting				that	10%	of	the	sample	group	did	not	display	any	signs	of	
withdrawal	and	did	not	require	any	medication.	Even	with	these	reductions,	no	patient	post-
intervention	developed	any	severe	signs	of	withdrawal	phenomena,	such	as	seizures	or	delirium	
tremens.	The	savings	to	the	trust	(The	Pennine	Acute	Hospital	Trust)	are	obvious,	but	the	
development	of	a	consistent,	quality	service	will	lead	to	fewer	long-term	negative	effects	for	patients	
that	can	be	caused	by	detoxification.	This	work	is	a	project	evaluation	of	a	locally	implemented	
strategy,	which,	it	was	hypothesised,	would	improve	care	by	providing	an	individualised	treatment	
plan	for	the	management	of	alcohol	withdrawal		symptoms.	
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Alcohol	abuse	and	dependence	represents	a	very	serious	health	problem	worldwide	with	major	social,		
interpersonal			and		legal	
consequences	(Amato	et	al,	 2010).	 Despite	an	increasing	awareness	of	its	dangers	among	both	the	
media	and	the	medical	 profession,	alcohol	remains	a	serious	and	growing	public	health	concern	in	the	
UK	(Owens	et	al,	2005).	According	to	Alcohol	Concern	(2010),	the	number	of	dependent	drinkers	in	
England	now	stands	at	1.6	million.	The	number	of	alcohol-	related	admissions	in	England	is	about	 one	
million	per	year	and	has	been	steadily	rising	(Perkins	and	Hennessey,	2014),	an	increase	of	100%	since	
2002/3	(Alcohol	Concern,	2010).	
Alcohol	Concern	states	that	the	cost	to	the	NHS	is	£2.7	billion	every	year	and	is	expected	to	continue	to	
rise	to	£3.7	billion	(Alcohol	Concern,	2010).	Although	alcohol	use	and	abuse	are	common	among	general	
hospital	 inpatients,	 many	 patients	 are	 inadequately	 assessed	 and	 treated	 for	 alcohol	 withdrawal	
(Repper-Delisi	et	al,	2008).	
Alcohol	withdrawal		syndrome		(AWS)		is		a	cluster	of	symptoms	that	may	develop	in	alcohol-dependent	
people	after	 the	cessation	of	 (or	 reduction	 in)	heavy	and	prolonged	alcohol	use	(American	Psychiatric	
Association	 (APA),	 2000;	World	 Health	 Organization	 (WHO),	 2010).	 AWS	 inevitably	 occurs	 as	 alcohol	
consumption	 ceases	 on	 admission	 to	 hospital,	 whether	 specifically	 for	 detoxification	 (‘detox’)	 or	 as	 a	
consequence	of	admission	for	other	problems.	
This	 project	 arose	 from	 the	 trust’s	 alcohol	 specialist	 nurse’s	 perception	 that	 the	 team	 tended	 to	 be	
approached	to	consult	on	alcohol	detoxification	only	when	things	went	 slightly	
  
‘wrong’	 such	as	when	a	patient’s	symptoms	exacerbated	and	 he/she	 	became	 	difficult	 	and	 time-
consuming	 to	 manage.	 They	 were	 worried	 about	 a	 lack	 of	 education	 in	 all	 clinicians	 about	
detoxification	and	a	lack	of	evidence-based	protocols	to	assist	in	patient	care.	A	significant	number	
of	critical	incidents	involving	patients	who	were	undergoing	detoxification	added	to	the	need	for	a	
project	 to	 implement	 and	 evaluate	 evidence-based	 approaches	 to	 the	 management	 of	 alcohol	
detoxification.	This	project	 	was	 	developed	to	standardise	alcohol	detoxification	regimes	across	a	
single-site	hospital	due	to	perceptions	that	existing	regimes	were	not	evidence-based	and	were	not	
consistent.	
	
AWS	
The	 clinical	 presentation	 of	 	 AWS	 	 varies	 from	mild	 to	 serious.	 The	 onset	 of	 symptoms	 typically	
occurs	up	to	48	hours	after	the	last	consumption	of	alcohol,	and	up	to	72	hours			if	delirium	tremens		
are	 	 considered	 	 (Amato	 et	 al,	 2010).	 Delirium	 tremens	 occurs	 in	 only	 about	 5%	 of	 patients	
undergoing	 alcohol	 withdrawal,	 but	 has	 the	 highest	 mortality	 	 rate:	 5–20%	 in	 inappropriately	
managed	patients.	 It	 is	a	medical	emergency	and	is	an	advanced	state	of	autonomic	hyperactivity.	
There	is	substantial	individual	variation	in	the	clinical	manifestations	of	alcohol	withdrawal,	ranging	
from	very	mild	tremor	and	irritability	to	significant	autonomic	hyperactivity	(e.g.	sweating	or	pulse	
rate	greater	than	100	beats	per	minute	(APA,	2000;	Wetterling	et	al,		2001;	Amato	et	al,	2010).	The	
Diagnostic	and	Statistical	Manual	of	Mental	Disorders			(DSM-	
IV)	 (APA,	 	 2000)	 	 continues	 	 the	 	 symptom	 	 list	with	 the	 following	 symptoms:	 tremor,	 insomnia,	
nausea	 or	 vomiting,	 transient	 visual,	 tactile	 or	 auditory	 hallucinations	 or	 illusions,	 psychomotor	
agitation,	 anxiety	 and	 seizures.	 To	 define	 AWS,	 the	 patient	 must	 have	 two	 or	 more	 of	 these	
symptoms	following	cessation	or	reduction	of	alcohol	(McKeon,	2008).	
The	 relation	 between	 alcohol	 intoxication,	 dependence,	 tolerance	 and	 withdrawal	 is	 not	 fully	
understood.	But	we	do	know		that	there		is	a	clear	relation	between	alcohol	and	changes	
	
Development	of	the	tool,	education	and	 implementation	
Withdrawal	severity	varies	greatly	and	the	amount	of	medication	needed	to	control	symptoms	can	
also	vary	significantly.	Chlordiazepoxide	is	typically	used	in	practice	(NICE,	2010b),	and	was	therefore	
the	 drug	 of	 choice	 for	 the	 protocol,	 though	 diazepam	 and	 lorazepam	 can	 be	 equally	 efficacious	
(Asplund	et	al,	2004).	Chlordiazepoxide	is	usually	administered	in	predetermined	prophylactic	dosing	
schedules	varying	between	3	and	10	days	 (Daeppen	 et	 al,	 2002;	McGregor	 et	 al,	 2003;	 Saitz,	 2004;	
McKinley,		2005;	NICE,		2010b).	
Although	this	method	is	used	frequently	throughout	hospitals,	predetermined	fixed	dosing	regimens	
may	 subject	 many	 patients	 	 to	 unnecessary	 medication,	 over-sedation	 and	 longer	 hospital	 stays	
(Asplund	et	al,	2004;	Saitz	et	al,	2004;	Hardern	and	Page,	2005;	NICE,	2010a;	NICE,	2010b).	Saitz	et	al	
(2004)	
state	 that	 many	 patients	 can	 safely	 undergo	 withdrawal	 from	 alcohol	 comfortably	 and	 without	
pharmacological	intervention,	which	was	seen	in	the	results	of	this	project.	
It	is	clear,	then,	that	a	more	individualised	approach	to	management	would	benefit	patients.	This	was	
achieved	 using	 a	 symptom-	 triggered	 therapy	 protocol,	 consisting	 of	 monitoring	 patients	 and	
providing	 medication	 only	 when	 symptoms	 of	 alcohol	 withdrawal	 developed.	 Symptoms	 were	
identified	with	a	validated	assessment	 tool,	 the	 revised	Clinical	 Institute	of	Withdrawal	Assessment	
Scale	 (CIWA-ar)	 (McKeon,	 2008).	 The	 symptom-	 triggered	 approach	 has	 demonstrable	 success	
(Daeppen	et	al,	2002;	Day	et	al,	2004;	Hardern	and	Page,	2005)	and	is	recommended	by	NICE	(2010a).	
The	 CIWA-ar	 scores	 the	 severity	 of	 nausea,	 sweating,	 agitation,	headache,	 anxiety,	 tremor,	 sensory	
disturbances	 and	 orientation,	 and	 is	 easy	 to	 use	 (McKeon,	 2008).	 Repeated	 scoring	 at	 suitable	
  
intervals	 monitors	 the	 response	 to	 treatment	 and	 helps	 determine	 if	 further	 pharmacotherapy	 is	
needed.	
These	 tools	 were	 integrated	 into	 a	 single	 booklet,	 including	 a	 policy	 for	 detoxification	 and	 an	
integrated	care	pathway	(ICP)	in	which	nurses	were	enabled	to	administer	chlordiazepoxide,	with	the	
dose	 dependent	 on	 the	 symptom	 score.	 A	 steering	 group	 engaged	 with	 hospital	 directorates	 and	
gained	approval.	Plans	 for	hospital-wide	 implementation	were	put	 into	place,	which	 included	email	
alerts	to	all	consultants,	alcohol	link	nurses	and	allied	health	professionals.There	were	also	advertising	
posters,	and	articles	in	trust	magazines	and		on			notice			boards.		Before		 implementation,	
80	hour-long,	separate	teaching		sessions	were	delivered	by	the	alcohol	team	over	a	2-week	period	to	
all	 appropriate	 clinical	 staff.	 Implementation	 followed,	 assisted	 by	 a	 timely	 changeover	 of	 junior	
doctors	and	by		constant	encouragement	and	endorsement	of	the	ICP	by	the	alcohol	team	
Post-intervention	audit	
A	post-intervention	audit	 took	place	4	months	after	 the	 implementation	of	 the	policy	and	 ICP.	The	
same	method	and	audit	tool	were	used	to	obtain	data.	The	sample	group		was	the	same	size	as	the	
initial	 sample,	 recruited	as	consecutive	patients	and	 fulfilling	 the	same	criteria.	A	 staff-satisfaction	
questionnaire	was	also	used	to	gain	insight	into	clinicians’	thoughts	on	the	new	policy	and	ICP.	A	mix	
of	open	and	closed	questions,	sent	to	300	clinical	staff,	obtained	qualitative	 findings.	
	
Results	
Results	of		pre-implementation		audit	The	average	number	of	days	to	detox	a	patient	was	6.36.	On	
average	it	costs	£300	per	night	for	an	inpatient	stay,	making	the	average	cost	of	these	detox	attempts	
£1908.	The	average	dose	of	chlordiazepoxide	to	complete	an	inpatient	detox	was	563.3	mg.	Forty	
percent	of	patients	were	given	PRN	(when	required)	medication,	but	in	only	10%	of	these	(two	
patients)	was	the	reason	documented.	Six	of	the	prescriptions	did	not	use	chlordiazepoxide	but	other	
medication.	
There	were	a	number	of	prescribing	errors,	such	as:	
§ Dosing	regimens	prescribed	in	the	wrong	area	of	prescription	chart	
§ No	maximal	dose	entered	on	 chart	
§ Tapering	doses	that	increased	instead	of	decreased	
§ Prescriptions	that	had	fixed	doses	for	a	number	of	days	instead	of	decreasing	
§ Only	PRN	medication	written,	with	no	guidance	on	administration	
§ Four	 prescriptions	 had	 fixed	 dosing,	 so	 there	 was	 no	 reduction,	 which	 is	 needed	 in	
withdrawal	treatment.	
	
There	was	great	variation	in	the	prescribing	methods	used	when	reducing	chlordiazepoxide	and	in	the	
number	of	days	to	complete	a		detox	(4	to	10).	Most	importantly,	a	total	of		11	patients	developed	signs	
of	severe	AWS:	5	developed	delirium	tremens	and	6	had	post-	admission	seizures.	
	
Results	 of	 post-implementation	 audit	 The	 average	 number	 of	 days	 to	 complete	 detox	 	 after		
implementation		of		the		ICP	was	
2.48.	On	average	it	costs	£300	per	night	for	an	inpatient	stay,	making	the	average	 cost	of	these	detox	
attempts	£744.	The	average	dose	of	chlordiazepoxide	to	complete	an	inpatient	detox	was	167.2	mg.	
Chlordiazepoxide	was	the	only	drug	used.	Five	patients	required	no	chlordiazepoxide.	
With	the	CIWA-ar	scoring	chart,	it	was	clear	what	symptoms	the	patient	was	displaying.	The			nurse			
could	 	 	 then	 	 	 administer	 	 	 a	 dose	 of	 chlordiazepoxide	 as	 required	 to	 alleviate	 the	 symptoms.	
Documentation	had	improved	because	now	all	clinicians	were	using	the	same	paperwork	to	manage	
this	 patient	 group.	 Use	 of	 the	 CIWA-ar	 also	 identified	 exactly	 what	 symptoms	 the	 patient	 was	
displaying.	
  
Before	 the	 project,	 11	 people	 from	 the	 sample	 group	 developed	 severe	 signs	 of	 AWS	 such	as	
seizures	or	delirium	tremens.	Following	the	change,	no	patient	developed	severe	signs	of	AWS.	Clearly,	
this	 is	only	 for	 this	 sample	and	 a	 larger	 study	would	 have	 to	 be	 done	 to	 ensure	 this	 finding	 was	
accurate.	 However,	 in	 	 light	 of	 the	 theory	 behind	 the	 symptom-triggered	 approach,	 identifying	
symptoms	early	should	prevent	exacerbation.	
All	prescriptions	were	written	correctly	and	the	dose	of	administration	was		only	wrong		on	three	
occasions,	with	patients	not	having	 the	 right	 amount	 in	 accordance	with	 their	 CIWA-ar	 score.This	
was	put	down	to	nursing	error,	as	the	flow	chart	had	not	been	followed	correctly	and	this	triggered	
further	educational	 input	 (refresher	 sessions	 for	 individual	 nurses	were	given	where	 needed).	 No	
patients	from	this	sample	group	developed	signs	of	delirium	or	seizures	after	starting	the	ICP.	
A	 total	of	212	questionnaires	were	returned	by	a	full	range	of	clinical	staff,	from	consultant	 to	 staff	
nurse,	 97%	 of	 whom	 believed	 that	 the	 ICP	was	user-friendly.The	vast	majority	(98%)	 believed	 that	
there	 had	 been	 improvements	 in	 care	 for	 this	 patient	 group,	 and	 that	 detox	 was	 achieved	much	
quicker	and	was	of	benefit	both	to	them	(through	reduced	workload)	and	to	the	patients	themselves.	
From	 the	 questionnaires,	 the	project	team	concluded	that	clinicians	were	satisfied	with	the	change,	
mostly	because	of	 the	 benefits	 for	 patients.	The	 results	 identified	 that	 an	 increase	 in	 satisfaction	
correlated	directly	with	the	increase	in	compliance.	
It	 was	 hypothesised	 at	 the	 start	 of	 the	 project	 that	 the	 use	 of	 an	 evidence-based,	 symptom-	
triggered,individualised	approach	to	withdrawal	management,	if	used	in	an	acute	setting,	would	improve	
patient	care.	 	 It	 	was	 	thought	 	 that	 	 the	amount	of	chlordiazepoxide	administered	would	decrease,	
resulting	in	a	shorter	treatment	duration.	These	results	were		confirmed		by	the	Mann-Whitney	non-
parametric	 statistical	 test.	 This	 test	was	 chosen	 because	 there	was	no	 specific	 distribution	 for	 the	
population,	resulting	in	skewed	data.	The	statistics	were	analysed	with	STATA	software	and	resulted		in	
a	p	value	of		0.001		(p=0.001).	This		was	the	case	for	both	duration	of	treatment	and	the	amount	of	
chlordiazepoxide	administered,	thereby	confirming	the	hypothesis.	
Discussion	
The	results	of	the	pre-	and	post-implementation	audit	accords	with	findings	from	previous	researchers	
on	this	subject	(Sullivan	et	al,	1989;	Daeppen	et	al,	2002;	Day	et	al,	2004;	Saitz	et	al,	2004).	The	samples	
were	not	 case-controlled,	which	 some	might	argue	undermines	 the	conclusions.	Yet	the	 results	are	
too	 startling	 	 to	 be	 the	 result	 of	 coincidence	 (the	 statistical	 analysis	 showed	 that	 the	 likelihood	 of	
them	being	a	coincidence	is	just	0.01%).	
Figure	5	shows	that	 the	 time	 for	a	patient	to	 complete	a	detox	has	been	greatly	reduced	since	 the	
implementation	of	the	ICP.	Furthermore,	the	amount	of	chlordiazepoxide	needed	to	complete	a	detox	
has	also	fallen	significantly	(Figure	6).	
Even	 though	 significantly	 less	 chlordiazepoxide	was	 required	 in	 the	majority	 of	 cases	 to	manage	
AWS,	not	one	person	from	this	sample	group	developed	severe	signs	of	withdrawal.	 It	 is	most	 likely	
that	 this	 is	due	 	 to	 the	patients	being	assessed	more	frequently	with	a	validated	assessment	tool,	in	
conjunction	with	staff	having	an	increased	knowledge	of	the	withdrawal	process.	 It	also	provides	an	
individualised	treatment	plan.	The	fact	that	signs	and	symptoms	were	being	detected	earlier	ensured	
that	 patients	 were	 adequately	 medicated	 and	 autonomic	 responses	 were	 kept	 to	 a	 minimum,	
safeguarding	against		 the	development	of	severe	AWS.	
As	 a	 contained	 booklet,	 it	was	 clear	 that	 the	 ICP	was	allowing	staff	to	ensure	documentation	was	
correct	and	acting	as	a	guide	 to	guarantee	 that	staff	knew	exactly	when	to	assess	and	manage	the	
level	of	withdrawal	they	were	presented	with.	Documentation	as	a	whole	had	improved.	The	CIWA-ar	
score	 meant	 	 that	 staff	 identified	 individual	 symptoms	 of	 withdrawal	 instead	 of	 using	 broad	
terminolgy	and	grouping.	
  
If	these	results	are	translated	into		even		very	rough	costings,	the	savings	to	the	trust	are	obvious.	
Pre-implementation,	 the	 average	 cost	 of	 an	 inpatient	 stay	 for	 	 detoxification	 was	 	 £1908.	 Post-
implementation,	this		fell	 to	
£744.	 More	 importantly,	 fewer	 drugs	 were	 used.These	 drugs	were	 appropriate	 in	 all	 cases	 and	 no	
severe	symptoms	occured	in	any	of	the	patients	from	the	audit	sample.	
Implementation	 was	 not	 without	 its	 problems,	 however,	 and	 a	 key	 stage	 was	 the	 arrival	 of	 new	
doctors	in	the	trust,	which	really	moved	the	change	forward.The	policy	was	not	a	change	in	practice	for	
these	new	doctors,	who	accepted	it	as	trust	policy	and	began	to	use	it.To	an	extent,	then,	they	drove	
the	rest	of	the	clinical	team	to	use	the	ICP	and	move	the	care	of	this	patient	group	forward.	
From	the	point	of	view	of	 the	 	alcohol	 	 team,	which	had	spent	a	huge	amount	of	 time	and	energy	
educating	 and	 implementing	 the	 policy,	 the	 surge	 in	 referrals	 was	 a	 validation	 of	 its	 efforts.	 The	
increase	in	compliance	meant	more	patients	were	being	assessed	by	an	alcohol	specialist,	resulting	in	
in-depth	alcohol	histories,	appropriate	treatment	options,	prompter	discharges	and,	when	required,	
more	successful	detox	attempts.	The	alcohol	team	was	also	identifying	trends:	for	example,	it	noted	
early	on	that	not	all	patients	who	were	alcohol-dependent	showed	physical	signs	of	withdrawal	and	
required	medication	 to	 stop.	 Before	moving	 to	 the	 symptom-triggered	 approach	 to	management,	
patients	 would	have	 automatically	 been	 started	 on	 a	 	 	 prophylactic	 detox	 regime	 and	 could	 be	 in	
hospital	 for	up	to	10	days	to	complete	 it,	even	though	their	bodies	did	not	require	any	medication.	
Some	people	were	completing	detox	in	as		 little	 as	2	days.	
Both	 these	 last	points	 showed	nurses	 that,	 if	 looked	after	appropriately,	the	patients	required	 less	
management	 overall	 and	 spent	 less	 time	 in	 hospital.	 The	 alcohol	 team	 was	 also	 getting	 fewer	
complaints	from	its	patients	with	regard	to	treatment,	due	to	their	detox	being	managed	appropriately.	
An	early	 referral	 to	 the	alcohol	 team	showed	patients	 that	 the	 hospital	 was	 trying	 to	help	 them—
their	stay	 was	much	more	than	just	having	pills	four	times	a	day	and	they	had	proper	treatment	plans	
and	aftercare	organised.	
The	team’s	credibility	grew	within	the	hospital	due	to	improved	patient	care.Clinicians	could	see	that	
the	 ICP	 was	 indeed	 improving	 care,	 improving	 documentation,	 improving	 patient	 satisfaction	 and	
reducing	clinical	incidents.These	thoughts	were	reinforced	with	the	results	of	the	post-change	audit.	
	
Conclusion	
This	project	has	achieved	what	it	set	out	to	achieve:	an	evidence-based	integrated	care	pathway	for	a	
group	of	patients	for	whom		care	had	been	less	than	optimal,	resulting	in	repeated	detoxification	and	
poor	outcomes.	The	cost	savings,	both	in	terms	of	inpatient	stay	and	drug	use,	are	quantifiable.	The	
potential	benefits	of	fewer	repeat	episodes	of	detoxification	and	the	revolving-door	effect,	as	well	as	
the	greater	patient	satisfaction,	are	less	easy	to	quantify,	but	doing	so	remains	an	aim	for	future	work.	
Excessive	 drinking	 is	 currently	 the	 second	 greatest	 risk	 to	 public	 health	 in	 developed	 countries	
(Kaner,	2010).	Although	most	 of	 that	 risk	 is	 avoidable,	 the	 risk	 is	 clearly	 apparent	 with	 the	 large	
number	of	hospital	admissions	every	year.	As	many	as	one	 in	 three	A&E	attendees	have	consumed	
alcohol	immediately	before	their	presentation	and	more	than	two	in	three	entries	after	midnight	may	
be	alcohol	related	(Williams	et	al,	2005).	
The	 focus	on	alcohol	 is	becoming	more	apparent.	 Initiatives	 such	as	 the	Commissioning	 for	 	 	 	Quality				
and	 	 	 	 Innovation	 	 	 	 	 (CQUIN)	 payment	 framework	 enable	 commissioners	 to	 reward	 excellence	 by	
linking	a	proportion	of	healthcare	income	to	the	achievement	of	the	local	quality	improvement	goals.	
The	fact	that	alcohol	is	such	a	major	problem	for	patients,	but	is	also	now	linked	to	financial	gain	for	
trusts,	 makes	 it	 even	 more	 imperative	 that	 treatment	 is	 timely	 and	 effective.	 This	 project	
demonstrates	one	such	method.		
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Key Points 
n Despite	an	increasing	awareness	of	its	dangers	alcohol	remains	a	serious	and	growing	public	health	concern	in	the		UK	
n Alcohol-related	admissions	are	steadily	rising	and	although	alcohol	misuse	is	common	among	general	inpatients	many	are	inadequately	assessed	and	treated	for	alcohol	withdrawal	
n This	project	looked	at	ways	of	improving	the	management	of	patients	withdrawing	from	alcohol	and	changed		practice	
n A	‘symptom-triggered’	approach	to	managing	withdrawal	symptoms	in	an	acute	hospital	setting	is	achievable	and	can	improve	outcomes	for	patients,	and	reduce	treatment	duration	and	the	amount	of	medication			used	
n Alcohol	misuse	should	be	a	high	priority	on	every	hospital	trust’s	agenda—projects	such	as	this	one	can	improve	patient	experience	and	staff			awareness	
		
	
	
	
	
	
	
	
	
	
	
	
	
Box 1. Audit tool and rationale for   questions 
Was the alcohol ICP used in the management of this   patient? Important	to	identify	if	the	trust	guidelines	are	being		met	
Number of days to complete detox? Important	to	compare	pre-ICP	and	post-ICP	to	note	any			improvement	
How much chlordiazepoxide was  administered? Important	to	compare	pre-ICP	and	post-ICP	to	note	any			improvement	
If ICP not started, was PRN medication    used? This	will	identify	if	predetermined	dosing	regimes	are	used	and	whether	staff	are	trying	to	alleviate	further	symptoms	with	as-required	medication	
If PRN medication was used, was the reason identified in the notes? This	will	highlight	the	need	for	CIWA	scoring	system	that	is	part	of	ICP	to	improve	assessment	and	documentation	
What drug is used in the detox process? Will	see	if	we	are	using	the	best	available	pharmacology	to	manage	this	group	
Is there consistency with  prescribing? Are	the	medicines	prescribed	in	proper			place?	
Are all areas of the prescription chart  complete? This	will	identify	any	problems	with	medical	prescribing	
Did anyone develop delirium or seizure activity after starting on a   detox? This	will	help	identify	differences	between	symptom-triggered	management	and	predetermined	dosing	
  
in	neurotransmissions	in	the	brain	(McKinley,	2005).The	chronic	presence	of	alcohol	
on	the	brain	leads	to	neuroadaptation	and	affects	brain	receptors	because	the	brain	
tries	to	maintain	a	homeostatic	balance	(Hoffman	and	Tabakoff,	1996;	Amato	et	al,	
2010).	 Neurotransmitters	 transmit	 information	 between	 neurons	 via	 synapses,	
either	exciting	or	inhibiting	impulses	along	the	neurons	(McKinley,	2005).	Alcohol	acts	
as	an	antagonist	at	key	receptors—some	of	 the	key	changes	 involve	reduced	brain	
gamma-aminobutyric	 acid	 (GABA)	 levels	and	 GABA-receptor	 sensitivity	 (Gold	and	
Aronson,	2011).	Prolonged	intake	causes	adjustment	of	the	central	nervous	system,	
reducing	 the	 initial	 short-term	 effects	 (McKinley,	 2005).	 Abrupt	 cessation	 or	
withdrawal	 of	 alcohol	 intake	 causes	 a	 rebound	 stimulatory	 effect,	 resulting	 in	
autonomic	hyperactivity,	leading	to	symptoms	of	AWS	(McKinley,	2005).	
It	 is	 important	 to	 treat	 AWS	 in	 order	 to	 decrease	 the	 severity	 of	 symptoms,	
preventing	more	 severe	 alcohol	withdrawal	 phenomena	 such	 as	 seizures,	 delirium	
tremens	 and	 Wernicke’s	 encephalopathy,	 which	 can	 be	 fatal.	 The	 advances	 in	
knowledge	of	neurobiology	and	neurochemistry	have	prompted	the	use	of	drugs	in	
the	 treatment	 of	 alcohol	 dependence	 and	 withdrawal	 that	 will	 allow	 the	 GABA	
pathways	to	restore	normal	brain	function	(Amato	et	al,	2010).	There	is	a	variety	of	
differing	medications	 that	work	on	 the	GABA	neurotransmitters	 	 in	 	 the	 	brain	 	 to	
treat	AWS	
	
(Amato	et	al,	2010;	National	Institute	for	Health	and	Care	Excellence	(NICE),	2010a)	
and	 the	 trust’s	 alcohol	 steering	 group	 decided	 to	 develop	 a	 protocol	 based	 on	
benzodiazepines,	 which	 are	 widely	 recognised	 as	 the	 drug	 of	 choice	 for	
detoxification	(Daeppen	et	al,	2002;	 Asplund	et	al,	2004;	Saitz	et	al,	2004;	McKinley,	
2005;	Amato	et	al,	2010;	NICE,	2010a).	
Benzodiazepines	 relieve	 the	 symptoms	 of	 alcohol	 withdrawal	 and	 reduce	 the	
frequency	of	seizures	and	delirium	tremens	(Saitz	et	al,	2004)	by	acting	on	the	GABA	
receptors	 and	 thus	 stopping	 the	 autonomic	 responses	 that	 follow	 cessation	 of	
alcohol	(Asplund	et	al,	2004;	McKinley,	2005;	NICE,	2010a).		When	
administered	 appropriately,	 benzodiazepines	 will	 not	 only	 prohibit	 the	
development	of	AWS	but	also	normalise	brain	function	(Amato	et	al,	2010).	
insomnia,	nausea	or	vomiting,	transient	visual,	tactile	or	auditorythe	presence	of	
alcohol	tolerance,	the	presence	of	an	alcohol	withdrawal	syndrome	when	drinking	
has	ceased	or	been	reduced	(i.e.	physical	dependence	on	alcohol),	the	intake	of	
alcohol	to	relieve	signs	of	withdrawal,	and	the	presence	of	difficulties	in	controlling	
drinking,	with	a	strong	desire	or	compulsion	to	drink	(Hoffman	and	Tabakoff	1996).	
	
The	number	of	dependent	drinkers	in	England	now	stands	at	1.6	million	(Alcohol	
Concern	2010).		The	cost	to	the	NHS	is	2.7	billion	pounds	every	year	and	is	expected	
to	continue	to	rise	to	3.7	billion	(Alcohol	Concern	2010).	Although	alcohol	use	and	
  
abuse	are	common	among	general	hospital	inpatients,	many	patients	are	
inadequately	assessed	and	treated	for	alcohol	withdrawal	(Repper-Delisi	2008).		
Alcohol	Withdrawal	Syndrome	(AWS)	is	a	cluster	of	symptoms	that	may	develop	in	
alcohol	dependent	people	after	the	cessation	of	(or	reduction	in)	heavy	and	
prolonged	alcohol	use	(American	Psychiatric	Association	2000).	The	clinical	
presentation	varies	from	mild	to	serious	and	the	onset	of	symptoms	typically	appear	
up	to	forty-eight	hours	after	the	last	consumption	of	alcohol,	and	actually	up	to	
seventy-two	hours	if	we	consider	the	uncommon	case	of	delirium	tremens	(Amato	et	
al	2011).	Delirium	tremens	happens	only	in	about	5%	of	patients	undergoing	alcohol	
withdrawal	however	has	the	highest	mortality	rate	(5	to	20%	in	inappropriately	
managed	patients),	it	is	a	medical	emergency	and	is	an	advanced	state	of	autonomic	
hyperactivity.		There	is	substantial	individual	variation	in	the	clinical	manifestations	of	
alcohol	withdrawal,	ranging	from	very	mild	tremor	and	irritability	to	significant	
autonomic	hyperactivity	(e.g.	sweating	or	pulse	rate	greater	than	one	hundred)	
(Amato	et	al	2011,	Wetterling	et	al	2001,	Hoffman	and	Tabakoff	1996).		DSM-IV	
continues	the	symptom	list	with	the	following	symptoms;	tremor,	insomnia,	nausea	
or	vomiting,	transient	visual,	tactile	or	auditory	hallucinations	or	illusions,	
psychomotor	agitation,	anxiety	and	seizures	(American	Psychiatric	Association	2000).		
To	define	AWS,	the	patient	must	have	two	or	more	of	these	symptoms	following	
cessation	or	reduction	of	alcohol	(McKeon	2008).	
In	general	hospitals,	alcohol	withdrawal	often	causes	significant	management	
problems	and	complicates	the	management	of	a	wide	variety	of	concurrent	
conditions	(Foy	et	al	1997).		This	places	a	huge	burden	on	the	National	Health	Service	
(NHS).		Alcohol	Concern’s	(2011)	research	showed	that	the	number	of	hospital	
admissions	was	1.1	million	in	2009/2010,	a	100%	increase	since	2002/03.		
	
The	alcohol	specialist	nurses	noted	that	they		tended	to	be	approached	to	consult	on	
alcohol	detoxification	only	when	things	went	slightly	‘wrong’	and	were	worried,	
about		a	lack	of	education	in	all	clinicians	around	detoxification	and	a	lack	of	evidence	
based	protocols	to	assist	in	patient	care.	A	significant	number	of	critical	incidents	
around	patients	who	were	undergoing	detoxification	added	to	the	led	to	the	need	for	
  
a	project	to	implement	and	evaluate	an	evidence	based	approach	to	the	
management	of	alcohol	detoxification.	
	
	
The	Project	
The	project	consisted	of	three	phases	
• a	pre	intervention	case	note	audit	looking	at	the	method	of	detoxification,	the	
drugs	used	and	the	time	taken	
• the	development	of	an	evidence	based	protocol	for	the	management	of	
detoxification	along	with		the	education	of	staff	and	the	implementation	of	
the	protocol	
• a	post	intervention	case	note	audit	
	
	
The	pre	intervention	audit	
A	sample	of	fifty	patient	case	notes	were	analysed	in	the	pre-change	audit.		It	was	felt	
this	size	would	highlight	trends	in	the	total	population	and	was	a	sufficient	enough	
size	to	extract	adequate	findings.		This	was	a	convenience	sample	using	the	first	fifty	
patients	who	were	referred	to	the	alcohol	service	who	had	that	completed	a	detox	as	
an	inpatient.		All	patients	had	to	fit	the	ICD	10	classifications	of	alcohol	dependency.	
	
The	findings	gathered	from	this	were	taken	in	a	quantitative	format,	this	was	felt	
appropriate	to	make	smoother	comparisons	with	the	post-change	audit	to	complete	
the	audit	cycle.		The	medical	records	of	these	patients	were	manually	searched	to	
obtain	the	data	needed	in	accordance	with	the	audit	tool.	
Figure	1	
Audit	Tool	
	
1. Was	the	alcohol	ICP	used	in	the	management	of	this	patient?	
Important	to	identify	if	the	Trust	guidelines	are	being	met	
	
  
2. Number	of	days	to	complete	detox?	
Important	to	compare	pre	ICP	and	post	ICP	to	note	any	improvement	
	
3. How	much	Chlordiazepoxide	was	administered?	
Important	to	compare	pre	ICP	and	post	ICP	to	note	any	improvement	
	
4. If	ICP	not	commenced.		Was	PRN	medication	utilised?	
This	will	identify	if	predetermined	dosing	regimes	are	used	are	staff	trying	to	
alleviate	further	symptoms	with	as	required	medication	
	
5. If	PRN	medication	was	used	was	it	identified	in	the	notes	why?	
This	will	highlight	the	need	for	CIWA	scoring	system	that	is	part	of	ICP	to	improve	
assessment	and	documentation	
	
6. What	drug	is	used	in	the	detox	process?	
Will	see	if	we	are	using	the	best	available	pharmacology	to	manage	this	group	
	
7. Is	there	consistency	with	prescribing?	
This	will	identify	any	problems	with	medical	prescribing.		Are	the	medicines	
prescribed	in	proper	place?	Are	all	areas	of	Kardex	complete?	
	
8. Did	anyone	develop	delirium	or	seizure	activity	following	commencement	on	
a	detox?	
This	will	help	identify	differences	between	symptom-triggered	management	and	
predetermined	dosing.	
	
	
	
	
	
	
  
	
	
Development	of	the	tool,	education	and	implementation	
The	interrelationship	between	alcohol	intoxication,	dependence,	tolerance	and	
withdrawal	are	not	fully	comprehended,	but	a	clear	relationship	exists	between	
alcohol	and	alterations	in	neurotransmissions	in	the	brain	(McKinley	2005).		The	
chronic	presence	of	alcohol	on	the	brain	leads	to	neuroadaptation	and	affects	brain	
receptors	due	to	the	brain	trying	to	attempt	to	maintain	a	homeostatic	balance	
(Amato	et	al	2011,	Hoffman	and	Tabakoff	1996).		Neurotransmitters	transmit	
information	between	neurons	via	synapses.		They	either	excite	or	inhibit	impulses	
along	the	neurons	(McKinley	2005).		Alcohol	acts	as	an	antagonist	at	key	receptors,	
some	of	the	key	changes	involve	reduced	brain	gamma-aminobutyric	acid	(GABA)	
levels	and	GABA-receptor	sensitivity	(Gold	and	Aronson	2011).	GABA	allows	more	
chloride	to	enter	the	neuron,	making	the	depolarisation	of	neuronal	cell	membranes	
less	likely	thereby	inhibiting	the	cell	(McKinley	2005).		McKinley	(2005)	also	describes	
the	second	important	neurotransmitter	affected	by	chronic	alcohol	abuse	that	is	the	
excitatory	neurotransmitter	N-methyl-D-aspartate	(NMDA).		NMDA	regulates	neuron	
excitability,	increasing	depolarisation	of	the	neuronal	membrane	by	regulating	the	
flow	of	calcium	into	the	neuron.	Chronic	alcohol	misuse	results	in	a	decrease	in	GABA	
inhibitory	function	and	an	increase	in	NMDA	sensitivity	(Amato	et	al	2011).		
Prolonged	intake	causes	adjustment	of	the	central	nervous	system	(CNS),	reducing	
the	initial	short	term	affects	(McKinley	2005).		Abrupt	cessation	of	intake	of	alcohol	
or	withdrawal	causes	a	rebound	stimulatory	effect,	resulting	in	autonomic	
hyperactivity,	leading	to	symptoms	of	AWS	(McKinley	2005)	See	(Figure	1.).		It	is	
important	to	treat	AWS	in	order	to	decrease	the	severity	of	symptoms,	preventing	
more	severe	alcohol	withdrawal	phenomena	such	as	seizures,	delirium	tremens	and	
WE,	which	could	prove	fatal.		The	advances	in	knowledge	of	neurobiology	and	
neurochemistry	have	prompted	the	use	of	drugs	in	the	treatment	of	alcohol	
dependence	and	withdrawal	that	will	allow	the	GABA	pathways	to	restore	normal	
brain	function	(Amato	et	al	2010).	There	are	a	variety	of	differing	medications	that	
work	on	the	GABA	neurotransmitters	in	the	brain	to	treat	AWS	(Amato	et	al	2011	and	
NICE	2010).		These	drugs	include	benzodiazepine	GABAergic	medications,	which	
  
consists	of	mainly	benzodiazepine	and	non-benzodiazepine,	GABAergic	compounds,	
which	involve	carbamazepine,	gabapentin,	valproic	acid,	topiramate,	Gama-
hydroxybutyric	acid	(GHB),	baclofen,	flumazenil	and	many	more	besides	(Amato	et	al	
2011).	
It	was	decided	to	develop	a	protocol	based	on	Benzodiazepines	that	are	widely	
recognised	as	the	drug	of	choice	for	detoxification	(Saitz	et	al	(2011),	Amato	et	al	
(2010),	NICE	(2010),	McKinley	(2005),	Chad	et	al	(2004)	and	Daeppen	et	al	(2002)).	
	
Benzodiazepines	ameliorate	the	symptoms	of	alcohol	withdrawal	and	reduce	the	
frequency	of	seizures	and	delirium	tremens	(Saitz	et	al	2011).		Metabolic	and	cellular	
changes	do	not	resolve	with	cessation	of	drinking	(McKinley	2005).	Due	to	the	
changes	in	this	homeostatic	balance	of	the	brain	increased	autonomic	response	
develops	in	some	patients	presenting	itself	in	the	form	of	AWS.		This	is	why	
Benzodiazepines	are	required	to	act	on	the	GABA	receptors	mirroring	the	way	alcohol	
does	stopping	autonomic	responses	noted	following	cessation	from	alcohol	(NICE	
2010,	McKinley	2005	and	Chad	2004).		When	administered	appropriately	
Benzodiazepines	will	not	only	prohibit	the	development	of	AWS	but	by	working	on	
the	GABA	receptors	will	normalise	brain	function	(Amato	et	al	2010).	
Chlordiazepoxide	is	more	typically	used	in	practice	(NICE	2010b)	was	therefore	the	
drug	of	choice	for	the	protocol	however	Diazepam	and	Lorazepam	can	be	equally	
efficacious	(Chad	et	al	2004).		
Although	withdrawal	severity	varies	greatly,	and	the	amount	of	medication	needed	
to	control	symptoms	can	also	vary	significantly	Chlordiazepoxide	is	usually	
administered	in	predetermined	prophylactic	dosing	schedules	varying	between	three	
and	ten	days	(Saitz	et	al	2011,	NICE	2010b,	McKinley	2005,	Daeppen	et	al	2002	and	
McGregor	et	al	2002).	Although	this	method	is	used	frequently	throughout	hospitals,	
predetermined	fixed	dosing	regimes	may	subject	many	patients	to	unnecessary	
medication,	over	sedation	and	longer	hospital	stays	(Saitz	et	al	2011,	NICE	2010,	NICE	
2010b,	Hardern	and	Page	2005,	Chad	et	al	2004	and	McGregor	et	al	2002).	Saitz	et	al	
(2011),	states	that	many	patients	actually	undergo	alcohol	withdrawal	safely	and	
comfortably	without	pharmacologic	intervention.	
  
It		is	clear	then	that	a	more	individualised	approach	to	management	would	benefit	
patients.		Symptom-triggered	therapy,	which	consists	of	monitoring	patients	and	
providing	medication	only	when	symptoms	of	alcohol	withdrawal	appear	is	an	
alternative	and	could	individualise	and	improve	the	management	of	alcohol	
withdrawal	(Saitz	et	al	2011	and	NICE	2010b).	A	number	of	studies	have	
demonstrated	its	successful	use	(Daeppen	et	al	(2002)	Day	et	al	(2004)	Hardern	and	
Page	2005,	)	and	it	is	recommended	by	NICE	(2010)		
Symptoms	can	be	identified	by	the	use	of	a	validated	assessment	tool.		A	quick	and	
useful	assessment	tool	is	the	revised	Clinical	Institute	of	Withdrawal	assessment	
Scale	(CIWA-ar)	(McKeon	2008).		This	ten-item	scale	scores	the	severity	of	nausea,	
sweating,	agitation,	headache,	anxiety,	tremor,	sensory	disturbances	and	orientation	
(McKeon	2008).		Sullivan	et	al	(1989)	state	competent	nurses	can	carry	out	an	
evaluation	in	less	than	two	minutes	and	the	inter-rater	reliability	is	high.	Repeated	
scoring	at	suitable	intervals	depending	on	scoring	monitors	the	response	to	
treatment	and	helps	to	determine	if	further	pharmacotherapy	is	needed.	
	
Using	project	management	methodology	and	utilising	a	steering	group	of	
stakeholders	within	the	Trust,	a	policy	for	detoxification	with	an	integrated	care	
pathway	as	an	integral	part	of	it.	Hs	was	approved	by	all	governing	boards	of	all	
directorates	as	patients	might	be	detoxifying	in	any	Trust	clinical	area	and	it	was	
crucial	that	all	areas	used	the	policy.	This	agreement	was	reached	and	plans	for	
hospital	wide	implementation	put	into	place	which	included	email	alerts	to	all	
consultants,		alcohol	link	nurses,	and	allied	health	professionals	for	cascading	to	
teams	as	well	as	advertising	posters	and	articles	in	Trust	magazines	and	on	notice	
boards.	Prior	to	implementation,	eighty,	hours	long,		separate	teaching	sessions	were	
delivered	within	a	two	week	period	
The	period	after	implementation	day	and	the	weeks	after	were	spent	chasing	doctors	
to	change	prescriptions	from	tapering	prophylactic	doses	to	the	symptom-triggered	
approach	advocated	by	the	policy,	training	more	and	more	staff,	and	questioning	why	
nurses	who	were	aware	of	the	Policy	were	still	administering	medication	the	old	way.			
It	was	clear	no	matter	how	rigorous	propaganda	is	there	is	still	a	huge	proportion	of	
staff	who	apparently	have	never	seen	it	or	indeed	encountered	a	member	of	the	
  
alcohol	team,	a	link	nurse	or	their	ward	manager	in	the	weeks	before	its	
implementation.	Over	a	period	of	weeks	though,	the	alcohol	team	noticed	a	change	
in	practice	and	more	implementation	of	the	policy	and	ICP	and	this	was	helped	
hugely	by	the	changeover	of	junior	doctors	in	August.	They	did	not	need	to	change	
practice,	just	to	be	told	about	Trust	policy	and	this	heralded	a	step	change	in	practice.	
Doctors	began	to	use	the	ICP	and	ask	nurses	to	implement	it,	as	a	matter	of	normal	
practice.		
	
	
The	post	intervention	audit	
	
To	compete	the	audit	cycle,	the	author	completed	a	post-change	audit	four	months	
after	the	implementation	of	an	alcohol	withdrawal	policy	and	ICP.		The	same	method	
and	audit	tool	was	used	to	obtain	data.		However	the	sample	group	were	different	
patients,	although	all	met	the	same	criteria	as	pre-change	audit	and	the	sample	size	
was	the	same.	A	staff	satisfaction	questionnaire	was	also	be	used	to	gain	insight	into	
clinician’s	thoughts	on	the	new	policy	and	ICP.		A	mixture	of	open	and	closed	
questions	were	utilised	to	gather	qualitative	findings.	
	
Results	of	pre	implementation	audit	
	
	
	
	
  
	
• Average	Number	of	days	to	detox	a	patient	was	6.36	days.	
• On	average	it	costs	£300	per	night	for	inpatient	stay	therefore	the	average	
cost	of	these	detox	attempts	is	£1,908.	
• 	
	
	
• Average	number	of	milligrams	of	Chlordiazepoxide	to	complete	an	inpatient	
detox	was	563.3	mg.	40%	were	given	PRN	medication	but	in	only	10%	of	these	
(2	cases)	was	the	reason	for	this	documented	
• Six	of	the	prescriptions	did	not	use	Chlordiazepoxide	but	used	other	
medication.	
There	were	a	number	of	prescribing	errors	made	such	as:	-	
• Dosing	regimes	prescribed	in	the	wrong	area	of	prescription	chart		
• No	maximum	dose	entered	on	chart	
• Tapering	doses	that	increased	instead	of	reducing	
• Prescriptions	that	had	fixed	doses	for	a	number	of	days	instead	of	reducing	
• Only	PRN	medication	written	with	no	guidance	on	administration	
• 4	prescriptions	had	fixed	dosing	so	there	was	no	reduction	which	is	needed	in	
withdrawal	treatment	
• Large	amount	of	variation	noted	when	reducing	Chlordiazepoxide	
• Days	to	complete	a	detox	ranged	from	four	to	ten	days	
  
Most	importantly,	Eleven	patients	developed	signs	of	severe	AWS.		Five	developed	
the	‘Delirium	Tremens’	and	six	had	seizures	post	admission.	
	
	
	
Results	of	post	implementation	audit	
	
	
	
• Average	number	of	days	to	complete	detox	is	2.48	days	
• On	average	it	costs	£300	per	night	for	inpatient	stay	therefore	the	average	
cost	of	these	detox	attempts	is	£744.	
	
• Average	number	of	milligrams	of	Chlordiazepoxide	to	complete	an	inpatient	
detox	was	167.2	mg.	
• Chlordiazepoxide	was	the	only	drug	used	
  
5	patients	required	no	Chlordiazepoxide	
It	can	be	noted	that	with	the	use	of	the	CIWA-ar	scoring	chart	it	was	clear	what	
symptoms	the	patient	was				showing.		With	this	the	nurse	could	prescribe	X-amount	
of	Chlordiazepoxide	as	required	to	alleviate	the	symptoms.		Documentation	had	
improved	because	now	all	clinicians	were	using	the	same	paperwork	to	manage	this	
patient	group.	
All	prescriptions	were	written	correctly	as	per	ICP.		The	dose	of	administration	was	
only	wrong	on	three	occasions	with	patients	not	having	the	right	amount	in	
accordance	to	their	CIWA-ar	score.		This	was	put	down	to	nursing	error,	as	they	had	
not	followed	the	flowchart	correctly.	
No	patients	from	this	sample	group	developed	signs	of	delirium	or	seizures	post	
commencement	on	the	ICP.	
212	questionnaires,	consisting	of	a	mixture	of	closed	ad	open	ended	questions	were	
returned	by		a	full	range	of	staff	from	consultant	to	staff	nurse,	97%	of	whom	felt	that	
the	ICP		was	user	friendly.	98%	felt	that	there	had	been	improvements	in	care	for	this	
patient	group	and	felt	that	detox	was	no	much	quicker	and	was	of	benefit	both	to	
workload	and	to	the	patient	themselves.	
	
Discussion	
	
The	results	of	the	author’s	audit	cycle	mirror	previous	research	Daeppen	et	al	(2002),	
Day	et	al	(2004),Harden	and	Page	(2005)	and	Saitz	et	al	(2011).		Although	flaws	can	
be	noted	in	all	the	research	and	here,	because	the	two	groups	contain	different	
patients	and	the	sample	is	not	case	controlled,	this	might	be	felt	to	damage	any	
claims	made,	the	results	are	too	startling	to	be	the	result	of	coincidence.	
	
	
  
	
	
The	comparitive	graph	is	a	clear	indicator	that	the	time	for	a	patient	to	complete	a	
detox	has	greatly	been	reduced	since	the	implemetnation	of	the	ICP.	Furthermore,	
the	amount	of	Chlordiazepoxide	to	succesfully	complete	a	detox	was	also	shown	to	
decrease	significantly.	
	
	
Even	though	less	Chlordiazepoxide	was	required	in	the	majority	of	cases	to	manage	
AWS,	not	one	person	from	this	sample	group	developed	severe	signs	of	withdrawal.		
It	is	most	likely	that	this	is	due	to	the	patients	being	assessed	more	frequently	using	a	
validated	assessment	tool	in	conjunction	with	staff	having	an	increased	knowledge	of	
the	withdrawal	process	tha	before	the	introduction	of	the	ICP.		The	fact	that	signs	
and	symptoms	were	being	detected	earlier,	ensured	patients	were	adequetly	
  
medicated	and	autonomic	responses	were	kept	to	a	minimum	safeguarding	against	
the	development	of	severe	AWS.	
	
It	was	clear	that	the	ICP	as	a	contained	booklet	was	allowing	staff	to	ensure	
documentation	was	correct	it	was	acting	as	a	guide	to	guarantee	staff	knew	exactly	
when	to	assess	and	how	to	manage	the	level	of	withdrawal	they	were	presented	
with.	
	
If	these	results	are	translated	into	even	very	rough	costings,	the	savings	to	the	Trust	
are	obvious.		Pre	implementation,	the	average	cost	of	an	inpatient	stay	for	
detoxification	was	£1,908.	Post	implementation	this	reduced	to	£744.	More	
importantly,	less	drugs	were	used,	appropriate	drugs	were	used	in	all	cases	and	no	
severe	symptoms	displayed	by	any	of	the	patients	from	the	audit	sample,	which	was,	
as	in	the	pre	implementation	audit,	a	set	of	50	consecutive	referrals	to	the	service.		
	
Implementation	was	not	without	its	problems	however	and	a	key	stage	was	the	entry	
of	new	junior	doctors	to	the	Trust	which	really	move	the	change	forward.	The	policy	
was	not	a	change	in	practice	for	these	doctors	who	accepted	it	as	Trust	policy	and	
began	to	use	it,	thus,	to	an	extent,	forcing	the	rest	of	the	clinical	team	to	use	the	ICP	
and	move	practice	and	the	care	of	this	patient	group,	forward.		
For	the	point	of	view	of	the	alcohol	team	who	had	spend	an	huge	amount	of	time	and	
energy	educating	and	implementing	the	policy,	the	surge	in	referrals	was	a	validation	
of	their	efforts.	With	the	increase	in	compliance	came	the	increase	of	support	from	
alcohol	services,	with	the	team’s	early	input	and	support	ensured	that	a	full	alcohol	
history	was	obtained	and	motivation	assessed	leading	to	prompter	discharges	or	
more	successful	detox	attempts.		The	alcohol	team	were	also	identifying	trends	it	was	
noted	early	on	that	not	all	patients	who	are	alcohol	dependent	show	actual	physical	
signs	of	withdrawal	and	require	no	medication	to	stop.		Before	moving	to	the	
symptom	triggered	approach	to	management	patients	would	have	automatically	
been	commenced	on	a	prophylactic	detox	regime	and	could	be	in	hospital	for	up	to	
ten	days	to	complete	it	even	though	their	bodies	did	not	require	any	medication.		
Some	people	were	completing	detox	in	as	little	as	two	days.		Both	of	these	last	points	
  
were	showing	nurses	that	if	looked	after	appropriately	the	patients	in	the	long	run	
required	less	management	and	spent	less	time	in	hospital.	The	alcohol	team	were	
also	having	fewer	complaints	from	their	patients	with	regards	to	treatment.		Due	to	
their	withdrawals	being	managed	appropriately	and	being	referred	to	the	alcohol	
team	promptly	showed	that	the	hospital	was	trying	to	help	them,	their	stay	was	
much	more	than	just	having	pills	four	times	a	day	they	had	proper	treatment	plans	
and	aftercare	organised.			
The	team’s	credibility	was	growing	in	the	hospital	and	with	that	acceptance	of	the	
change	followed.		Clinicians	realised	that	the	ICP	was	indeed	improving	care,	
improving	documentation,	improving	patient	satisfaction	and	reducing	clinical	
incidents	and	the	benefits	of	its	use	became	clear,	backed	up	by	the	second	audit	
results.	
	
	
Conclusion	
This	project	has	achieved	what	it	set	out	to	achieve;	an	evidence	based	integrated	car	
pathway	for	a	group	of	patients	for	whom	care	had	been	less	than	optimum,	
resulting	in	repeated	detoxification	and	poor	outcomes.	The	benefits	of	the	cost	
saving,	both	in	terms	of	inpatient	stay	and	drug	use	are	quantifiable,	the	potential	
benefits	of	less	repeat	episodes	of	detoxification	and	the	revolving	door	effect,	as	
well	as	the	greater	patient	satisfaction	are	less	easy	to	quantity	but	this	remains	an	
aim	for	future	work.	
Excessive	drinking	is	currently	the	second	greatest	risk	to	public	health	in	developed	
countries	(Kaner	2010).	Although	most	of	that	risk	is	avoidable	the	risk	is	clearly	
apparent	with	the	large	number	of	hospital	admissions	every	year,	with	as	many	as	
one	in	three	attendees	having	consumed	alcohol	immediately	before	their	
presentation	and	more	than	two-thirds	of	attendances	after	midnight	may	be	alcohol	
related	(Crawford	et	al	2004).	The	emphasis	on	alcohol	is	becoming	more	apparent	
and	with	initiatives	such	as	Commissioning	for	Quality	and	Innovation	(CQUIN)	
payment	framework	enables	commissioners	to	reward	excellence	by,	linking	a	
proportion	of	healthcare	income	to	the	achievement	of	the	local	quality	
improvement	goals.	The	fact	that	alcohol	is	such	a	major	problem	and	is	linked	to	
  
payments	to	Trusts	makes	it	even	more	imperative	that	treatment	is	timely	and	
effective	and	this	project	demonstrates	one	such	method.	
		
